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The burden of renal disease
The incidence of end-stage renal disease [ESRD; stage 5
chronic kidney disease (CKD)] continues to increase in
Europe, particularly due to type 2 diabetes, hyperten-
sive renovascular disease or atherosclerosis [1–3]. In-
deed, across nine European countries (Austria, Belgium,
Denmark, Finland, Greece, Norway, Scotland, Spain and
the Netherlands) from 1990 to 1999, the adjusted incidence
of renal replacement therapy to treat ESRD increased by
∼5% per year [4]. Moreover, the adjusted overall incidence
of ESRD cases in treatment approximately doubled over
this 9-year period, from 12.7 to 23.6 per million population
due to diabetes, from 6.3 to 11.5 per million due to hyper-
tension, and from 3.6 to 7.6 per million population due to
renovascular disease [4]. The global prevalence of ESRD is
280 cases per million and is subject to regional variations;
the prevalence is lower in Europe (585 cases per million)
than in North America (1505 cases per million) and Japan
(2045 cases per million) [5].
In addition to the information on the incidence and preva-
lence of ESRD, multiple studies have shown a consider-
able number of individuals in the general population with
a slight-to-moderate decrease in renal function. This popu-
lation may have an increased risk of ESRD compared with
those without renal impairment. Prevalence data from the
USA [6] and Europe [7,8] are consistent, with∼10% of the
general population having stage 1–3 CKD.
Risk factors for the development of ESRD include di-
abetes, hypertension, obesity, dyslipidaemia, history of
smoking, anaemia and proteinuria/albuminuria. Diabetic
nephropathy occurs in up to 40% of diabetic subjects
with microalbuminuria and is currently the major cause
of ESRD in many regions of the world [9–13]. Worldwide,
more than 180 million people are estimated to have dia-
betes, and this number is projected to more than double by
2030 [14].
Clearly, we need an armamentarium of intervention,
as well as prevention measures, to reduce the burden of
renal disease now and in the near future. Several such
risk management strategies have been tested, targeting
risk factors such as hyperglycaemia, hypertension, dyslipi-
daemia and albuminuria/proteinuria in addition to lifestyle
changes [15–20]. Intensive management of all risk factors
in diabetes is clearly important in preventing or slowing
nephropathy progression [11,21–23]. This armamentarium
is needed not only to improve the health of the popula-
tion concerned, but also to provide lifetime net cost savings
with long-term financial benefits offsetting the potential
high initial investment costs in preventive strategies.
The increasing incidence of ESRD presents a consider-
able financial burden. Renal dysfunction (decreased eGFR)
andESRDare associatedwith highmorbidity andmortality,
and high treatment costs [9,11,24,25]. The primary objec-
tive of this paper is to provide an overview of the economic
value, from a European perspective, of various pharma-
cotherapeutic interventions, in slowing renal progression
in type 2 diabetic nephropathy.
Drug treatment in diabetic renal disease
Pro-active encouragement of life-style changes and drug
treatment to prevent or reduce the progression of cardio-
vascular and renal disease is currently the main approach to
treating type 2 diabetes. The benefits of tight blood pressure
and glycaemic control, and anti-dyslipidaemic (e.g. statins)
and anti-platelet (e.g. aspirin) interventions are now firmly
established with regard to reduced progression of cardiac
and renal events [26–30]. These studies show that the risk
of these events is best reduced by effectively controlling
high blood pressure, although it is also beneficial to initiate
antihypertensive therapy in nonhypertensive patients with
type 2 diabetes [31]. The choice of the exact antihyperten-
sive agent is important, since the classes of antihypertensive
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agents that intervene in the renin–angiotensin system may
be more effective than the other classes [32,33]. Addition-
ally, safety differences between agents may prove to be
even more prominent than potential efficacy differences.
This applies to late intervention as well as early interven-
tion strategies [34]. The current (artificial) staging of pre-
vention and intervention therapies deals with the following
criteria: (i) prevention of the development of diabetes; (ii),
when the disease is present, prevention of switching from
normoalbuminuria to microalbuminuria and (iii) switching
from microalbuminuria to overt nephropathy. These strate-
gies may be labelled prevention and/or early intervention,
whereas late intervention could be defined as postponing or
preventing dialysis or transplantation in patients with overt
nephropathy.
Genetic polymorphisms of the angiotensin-converting
enzyme (ACE) gene are thought to be involved in the re-
sponse to treatment. A recent subanalysis of the RENAAL
(Reduction of Endpoints inNon-insulin-dependent diabetes
mellitus with theAngiotensin II Antagonist Losartan) study
in proteinuric patients with type 2 diabetes showed that,
unlike the ACE II allele, the D allele of the ACE gene
[insertion (I)/deletion (D) and D/D] was associated with
an unfavourable renal prognosis, which was improved with
losartan therapy [35]. Similar findings from the REIN trial
in non-diabetics led to one specific economic analysis on
whether or not to genetically screen prior to treatment ini-
tiation [36].
Prevention of diabetes
Data from secondary analyses of several studies reveal that
ACE inhibitors and angiotensin receptor blockers (ARBs),
administered to patients without diabetes, but with vari-
ous cardiovascular conditions, can reduce the risk of new-
onset type 2 diabetes by up to 25% [37]. Examples are
the DREAM study (Diabetes Reduction Assessment With
Ramipril and Rosiglitazone Medication) and the LIFE
(Losartan Intervention For Endpoint reduction in hyperten-
sion) study. The first showed that ramipril therapy signif-
icantly increased regression to normoglycaemia compared
with placebo (P=0.001) [38]. The second showed that new-
onset diabetes occurred significantly less frequently (P =
0.001) in the losartan- than in the atenolol-treated group
(13.0 versus 17.4 per 1000 patient-years of follow-up)
[39].
Prevention of microalbuminuria
ACE inhibitors have been shown to prevent or delay the de-
velopment of microalbuminuria in normoalbuminuric pa-
tients with type 2 diabetes. The BENEDICT (Bergamo
Nephrologic Diabetes Complication Trial) study showed
that treatment with trandolapril slowed the onset of persis-
tent microalbuminuria by 53%. Interestingly, in the control
arm of this study where the antihypertensive verapamil was
used alone, there was no reduction in the development of
microalbuminuria. This clearly shows that, although blood
pressure control is important in diabetes, using an interven-








































Fig. 1. ARBs reduce the risk of diabetic nephropathy progression: data
shown (relative risk reductions versus placebo) are for the primary com-
posite endpoint of doubling of serum creatinine, onset of ESRD or death
from any cause (IDNT [50] and RENAAL [49] trials); or for the pri-
mary outcome of time to the onset of diabetic nephropathy (IRMA-2
trial [41]). ARB, angiotensin receptor blocker; IDNT, Irbesartan Diabetic
Nephropathy Trial; IRMA-2, irbesartan in reduction of microalbuminuria-
2; RENAAL, Reduction of Endpoints in Non-insulin-dependent diabetes
mellitus with the Angiotensin II Antagonist Losartan.
is of important additive value in protective prevention of
renal disease [40].
Early intervention
The IRMA-2 (Irbesartan in Reduction of
Microalbuminuria-2) study was the first to demon-
strate that ARBs can prevent the further development
of albuminuria in hypertensive type 2 diabetic patients
with microalbuminuria, and delay progression to overt
nephropathy (Figure 1) [41]. Over a 2-year period, irbesar-
tan effectively maintained low levels of microalbuminuria
and exerted an independent renoprotective effect that was
sustained after the cessation of treatment. Overt diabetic
nephropathy was reached in 14.9% of placebo-treated par-
ticipants, and in 9.7% and 5.2%of those receiving low- (150
mg) and high-dose (300 mg) irbesartan, respectively [41].
That RAAS inhibition could prevent transition from mi-
croalbuminuria to overt nephropathy was confirmed in
the randomized, double-blind INNOVATION (INcipient to
OVert: Angiotensin II blockers, Telmisartan, Investigation
On type 2 diabetic Nephropathy) study [42] in hyperten-
sive and also in normotensive Japanese patients with type 2
diabetes. With a mean follow-up time of 1.3 years, the tran-
sition rates to overt nephropathy were 16.7% and 22.6%
with telmisartan 80 mg/day and 40 mg/day, respectively,
compared with 49.9% with placebo (P <0.0001 for both
telmisartan doses versus placebo) [42].
Even at very low levels, microalbuminuria is strongly
correlated with cardiovascular risk in diabetes patients [43].
The HOPE (Heart Outcomes Prevention Evaluation) study
showed that, over a 4.5-year period, ACE inhibitor therapy
reduced the risk of cardiovascular events by 25% in patients
with type 2 diabetes and microalbuminuria [44].
In the Steno-2 study, patients with type 2 diabetes and
microalbuminuria received either conventional antihyper-
tensive therapy (n = 80) or intensive antihypertensive ther-
apy with either ACE inhibitors or ARBs (n = 80) for
a mean treatment duration of 7.8 years [22]. At follow-
up (mean 13.3 years), intensive early intervention with
ACE inhibitors or ARBs reduced the risk of cardiovascular
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disease, nephropathy and death by 59%, 56% and 46%,
respectively [45].
Recently, the ADVANCE (Action in Diabetes and Vascu-
lar Disease: Preterax and Diamicron-MRControlled Evalu-
ation) study considered the impact of antihypertensive ther-
apy for early to late-phase prevention in patients with type
2 diabetes regardless of hypertensive or renal status [28].
ADVANCE investigated the effect of an ACE inhibitor
and diuretic in combination on major macrovascular and
microvascular events. After a mean 4.3 years’ follow-up,
active therapy reduced the relative risk of a major event
by 9% (P = 0.04), and the relative risk of death from
cardiovascular disease was reduced by 18% (P = 0.03)
[28].
Late intervention
Patients with type 2 diabetes and overt nephropathy are
at high risk of cardiovascular events and progression
to ESRD; therefore, prompt initiation of antihyperten-
sive treatment is recommended [46]. ACE inhibitors and
ARBs markedly reduce the risk of cardiovascular events
in these patients [44,47,48]. Large, double-blind, multicen-
tre, placebo-controlled studies such as RENAAL [49] and
IDNT (Irbesartan Diabetic Nephropathy Trial) [50] have
suggested that ACE inhibitors and ARBs are able to slow
the rate of progression of diabetic nephropathy via blockade
of RAAS constituents (Figure 1).
ACE inhibitors have been studied with particular respect
to their effect on the progression of cardiovascular disease,
whereas the effects of ARBs in patients with type 2 dia-
betes have been assessed against specific endpoints reflect-
ing kidney performance, with some consideration given to
competing cardiovascular events [51]. Although this cre-
ates a sound rationale for combination therapy with an
ACE inhibitor and an ARB in patients with overt nephropa-
thy, recent data from the Ongoing Telmisartan Alone
and in Combination with Ramipril Global Endpoint Trial
(ONTARGET) question the value of such an approach.
Combined treatment with the ARB telmisartan and the
ACE inhibitor ramipril appeared to worsen major renal out-
comes, compared with either agent alone [52]. Currently,
at least two studies have been started that further study the
effect of combination therapy on renal hard outcomes: the
LIRICO (Long-term Impact of RAS Inhibition onCardiore-
nal Outcomes study [53]) and the VA-NEPHRON-D study
[54].
Unfortunately, direct comparisons between ACE in-
hibitors and ARBs are generally limited to small studies,
and are often not based on rigorously defined renal end-
points. The DETAIL study showed that telmisartan was not
inferior if directly compared to enalapril on the primary
endpoint of glomerular filtration [55]. Also, the effects of
both drugs on the secondary endpoints (inclusive rates of
ESRDand cardiovascular events)were not significantly dif-
ferent after 5 years. The ROAD (Renoprotection of Optimal
Antiproteinuric Doses) study in non-diabetic nephropathy
patients clearly showed similar effects of ACEi and ARB
intervention on hard renal outcome [56]. In diabetes, no
such studies have been reported yet.
Pharmacoeconomic studies in type 2 diabetic
renal disease
The management costs associated with albuminuria and
cardiovascular complications of kidney disease are sub-
stantial [57]. Caro and colleagues estimated that, of the
total costs involved in the care of patients with type 2 dia-
betes, the costs of managing macrovascular complications
comprise the largest component, accounting for 85% of
the cumulative costs over the first 5 years and 77% over the
first decade [58]. In the USA, the total annual cost of ESRD
in patients with type 2 diabetes is projected to increase to
more than $39 billion by 2010 [25]. Data from France and
Belgium suggest that ESRD dialysis costs the health ser-
vices ∼€44 000–61 000 per patient annually [59]. An-
nual costs of transplantation per ESRD patient from Dutch,
French and Belgian studies have been estimated to be
€25 000–50 000 in the first year [59,60]. Other data have
shown the average cost of treating ESRD in the UK to be
∼£20 802 (∼€25 000) per patient per year [61] and the
annual cost of dialysis to be £30 000 (∼€35 500) [62],
whereas ESRD costs in Germany in 1999 were estimated
at €40 414 per patient per year [63] and, in France, the
estimated annual expenditure per ESRD patient in 2003
was ∼€41 000 [24]. Finally, in their economic analysis on
the REIN trial, Costa-Scharplatz [36] analysed a range for
dialysis costs for European Union countries from €20 000
to €80 000, with €48 170 as the most likely value (repre-
senting the German situation).
Halting the progression to ESRD would appear to be the
obvious goal in type 2 diabetic renal disease, thus saving
on costs of dialysis care or transplantation for patients who
have no remaining kidney function. Intervention at the mi-
croalbuminuria and overt nephropathy stages can prevent
or slow the progression to ESRD. A lot of effort, in terms
of time and cost of treatment, in patients with a relatively
low chance of reaching ESRD (i.e. all those with microal-
buminuria) would appear at first sight to be costly due to
the high numbers needed to treat. However, analyses com-
paring early and late interventions have demonstrated that
early treatment with irbesartan in hypertensive patients with
type 2 diabetes and microalbuminuria is likely to improve
life expectancy and reduce overall costs compared to later
treatment in patients who had already progressed to overt
nephropathy [64,65].
Late intervention
A number of European pharmacoeconomic studies have
quantified the cost savings that can be attained by inter-
vening with ARB therapy to slow renal disease progression
in type 2 diabetic patients with overt nephropathy (urinary
albumin excretion >300 mg/24 h) (Table 1) [66]. Analy-
ses using Markov modelling on data from IDNT revealed
projected cost savings, over 10–25 years, of up to €27 611
per patient treated with irbesartan versus amlodipine, due
to slowing of the progression from overt nephropathy to
ESRD; corresponding cost savings for irbesartan versus










Table 1. Pharmacoeconomic analyses of pharmacotherapy for slowing of renal disease progression in type 2 diabetic patients with overt nephropathy
Reduction in
Projected time relative risk of
Base study frame of Parameters progression to Estimated ESRD-related
Reference Pharmacotherapy data Countries analysis evaluated ESRD Key findings cost savings per patient
Palmer et al.
2005 [68]
IRB AML IDNT [50] Belgium, France, Germany,
Hungary, Italy, Spain, UK,
USA
4 years Clinical and cost outcomes
(over a 25-year timeframe)
from 7 studies
23%∗ IRB improved DLE by up to
0.65 years versus AML,
and by 0.36–0.76 years
versus control
€10 158–€27 611 for IRB
versus AML, and




IRB AML IDNT [50] UK 4 years Mean 10-year costs and
changes in DLE
23%∗ IRB improved DLE by 0.07
years versus AML, and by
0.21 years versus control
£5125 for IRB versus AML,




IRB AML IDNT [50] Belgium, France 4 years Mean 10-year costs and
changes in DLE
23%∗ IRB improved DLE by 0.13
years versus AML, and by
0.26 years versus control
€14 949–€20 128 for IRB
versus AML, and




LOS RENAAL [49] EU 4 years Burden and costs of ESRD 29% 51 800 fewer ESRD cases;





LOS RENAAL [49] Nordic region (Denmark,
Finland, Norway, Sweden)
4 years Costs associated with ESRD 29% Mean medical costs per
patient during the first year




LOS RENAAL [49] France 4 years Cost savings associated with
reduced ESRD days
29% €7438 per patient
Szucs et al.
2004 [71]
LOS RENAAL [49] Switzerland 4 years Number of ESRD days saved 29% 33.6 ESRD days saved CHF10 086 per patient
Vora et al.
2005 [62]
LOS RENAAL [49] UK 4 years Life-years saved 29% Projected mean life-years
saved = 0.44
£7390 per patient
aTotal, not per patient.
AML, amlodipine; CHF, Swiss Francs; DLE, discounted life expectancy; ESRD, end-stage renal disease; EU, European Union; IDNT, Irbesartan Diabetic Nephropathy Trial; IRB, irbesartan; LOS, losartan;
RENAAL, Reduction in Endpoints in Non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan.
∗Relative to placebo, but also amlodipine.
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Table 2. Irbesartan improves discounted life expectancy and saves costs relative to amlodipine and conventional antihypertensive therapy in patients
with type 2 diabetes, hypertension and overt nephropathy: data from a systematic review of seven published cost-effectiveness analyses [68]
Increase in discounted life expectancy (years/patient)a Cost savings (€/patient)b
Country IRB versus AML IRB versus CAT IRB versus AML IRB versus CAT
Belgium 0.46 0.62 21 798 12 241
France 0.45 0.61 27 611 16 688
Germany – – 15 445c 9338c
Hungary 0.15 0.36 10 158 5336
Italy 0.30 0.46 17 003 9418
Spain 0.21 0.37 14 083 7861
UK 0.31 0.58 13 457 7300
USA 0.65 0.76 21 585 12 810
Adapted from Palmer AJ et al. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial
Transplant 2005; 20: 1103–1109, by permission of Oxford University Press on behalf of ERA-EDTA. Copyright C© 2005 ERA-EDTA.
a25-year time frame; discount rate 1.5–6%.
b25-year time frame; discount rate 3–6%.
c10-year time frame; discount rate 5%.
AML, amlodipine; CAT, conventional antihypertensive therapy; IRB, irbesartan.
Palmer et al. performed a systematic review of seven
cost-effectiveness analyses that applied IDNT data to
Belgium, France, Germany, Hungary, Italy, Spain, the UK
and the USA [68]. Within the framework of a Markov
model, the mean time to the onset of ESRD was estimated
to be 8.23 years for irbesartan, 6.82 years for amlodipine
and 6.88 years for placebo, respectively; moreover, the
corresponding mean cumulative incidences of ESRD were
36%, 49% and 45%. Irbesartan improved discounted life
expectancy, projected over a 25-year period, by up to
0.65 years relative to amlodipine and by 0.36–0.76 years
versus control (Table 1). In addition to these benefits,
irbesartan was estimated to produce major cost savings
over 25 years (up to €27 611 per patient; Tables 1 and 2);
the latter savings generally manifested within 2–3 years of
starting treatment [68].
Several pharmacoeconomic evaluations have applied
RENAAL study data to European regions (Table 2)
[62,63,69–71]. One analysis reported that treatment with
losartan, to delay the progression of overt nephropathy to
ESRD, would save an estimated €3.6 billion over 4 years
throughout the European Union; these savings were associ-
ated with a predicted decrease of more than 50 000 cases of
ESRD and 89 900 person-years living with ESRD avoided
[63]. Other analyses—using costing designs or decision
analytic techniques—documented per-patient cost savings
of∼€2687–7500 in Nordic countries [69], France [70] and
Switzerland [71]. From the UK National Health Service
payer perspective, losartan was estimated to statistically
significant save overall health-care costs if compared with
conventional antihypertensive therapy [62]. Sensitivity
analyses revealed that losartan therapy remained cost
saving in all cases, even if the costs of renal replacement
therapy for ESRD were halved. Furthermore, losartan ver-
sus conventional antihypertensive therapy was associated
with a projected mean number of life-years saved of 0.44
(P= 0.002) due to a reduction in the relative risk for ESRD
[62].
To date, there have been no direct comparisons between
ARBs and ACE inhibitors in terms of cost-effectiveness.
Using indirect comparisons, ACE inhibitors are far more
economic in terms of pricing, whereas ARBs have ad-
vantages on safety [72]. Obviously, such comparisons are
highly sensitive to the exact assumptions applied.
In summary, results from economic studies have shown
that late intervention with RAAS-inhibiting agents, to de-
lay the progression of overt nephropathy to ESRD, provides
substantial cost savings versus conventional antihyperten-
sive therapy [73]. In strict pharmacoeconomic terminology,
this would mean that such treatments represent ‘dominant’
interventions.
Early intervention
The high residual risk—and the high residual treatment
costs—of type 2 diabetic patients with overt nephropathy
during consequential ARB or ACE inhibitor treatment, as
observed in RENAAL, IDNT and other studies, suggests a
need to intervene earlier in the course of this progressive
condition, for example, upon detection ofmicroalbuminuria
in patientswith type 2 diabetes or earlier. Indeed, the IRMA-
2 study showed that ARBs could delay the progression of
microalbuminuria to overt nephropathy [41]. Several cost-
effectiveness analyses have been performed using these data
[60,74–77].
In one analysis, a Markov model was used to assess
the health economic impact of screening for albuminuria
using urinary dipstick testing in a primary care setting in
French type 2 patients with hypertension [74]. In patients
with microalbuminuria or overt nephropathy, treatment
with irbesartan 300 mg/day was added to conventional
antihypertensive therapy. Screening, and subsequently
optimized therapy, for albuminuria reduced the cumulative
incidence of ESRD by 42%, improved life expectancy
by 0.38 years, produced an improvement of 0.29 quality-
adjusted life years (QALYs) and reduced ESRD-related
costs by €4812 per patient, over a projected time frame of
25 years [74]. Similar favourable results were found by the
same investigators in a US setting [78].
An economic analysis in the Netherlands showed the
cost-effectiveness of recommendations, in national clinical
guidelines, for the prevention of type 2 diabetic nephropathy
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[60]. Treatment of patients with type 2 diabetes according
to clinical guidelines produced a gain of 0.2 complication-
free life years, with a cost-effectiveness ratio of ∼€14 000
per QALY. With over half a million of diabetes patients
in the Netherlands, strict adherence to guidelines may
therefore gain ∼100 000 complication-free life years
[60].
Several other analyses support the benefits of early phar-
macological intervention in patientswith hypertension, type
2 diabetes and microalbuminuria (Table 3) [75–77]. All
these studies indeed found the dominant situation of cost
savings combined with favourable health effects for ARB
therapy.
A recently published economic analysis of Steno-2 from
a Danish healthcare payer perspective also found accept-
able pharmacoeconomics of intensive early intervention
in patients with type 2 diabetes and microalbuminuria
[79]. Intensive antihypertensive treatment increased life
expectancy with a corresponding discounted incremental
cost-effectiveness ratio of €2538 per QALY gained com-
pared with conventional treatment, which, as a conservative
estimate, is well within accepted cost-effectiveness limits.
A sensitivity analysis showed that intensive therapy be-
came dominant if all patients were treated in a primary care
setting.
Prevention of diabetes
There are no published pharmacoeconomic analyses of pre-
venting new-onset diabetes through RAAS treatment. Of
note, the PREVEND cohort has shown that microalbumin-
uria levels (and even high normal levels of albuminuria)
are associated with increased risk for developing new-onset
diabetes [80]. Prospective studies of looking into the cost-
effectiveness of preventing diabetes could be interesting,
particularly in light of the finding that early intervention is
potentially more cost-effective than late.
Prevention of microalbuminuria in patients with diabetes
At present, there are no data on the cost-effectiveness of
preventing the development of microalbuminuria in pa-
tients with diabetes in clinical practice. Whether albumin-
uria lowering will reduce the rate of new-onset diabetes and
subsequent economic burden would be an interesting focus
of future research.
Early or late intervention: which is best?
Recently, Palmer and colleagues conducted a cost-
effectiveness analysis in the French setting, in which early
or late intervention with ARB therapy was compared with
conventional antihypertensive therapy in hypertensive pa-
tients with type 2 diabetes and microalbuminuria or overt
nephropathy [65]. A Markov model was used to simulate
the progression from microalbuminuria to overt nephropa-
thy, doubling of serum creatinine, ESRD and total mortality
over a 25-year period. Transition probabilities were derived
from IDNT, IRMA-2 and other sources. Relative to con-
ventional antihypertensive therapy, early versus late ARB
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versus 0.06 QALYs and saved €22 314 versus €6619 per
patient. Thus, although late intervention with ARB therapy
was clearly beneficial, earlier intervention had advantages
in terms of markedly greater life expectancy and improved
quality of remaining life, and considerably greater cost sav-
ings [65]. These findings reinforced previous findings by
the same authors [56].
Golan et al. performed a cost-effectiveness analysis of
prescribing ACE inhibitors to all patients aged 50 years
or older with newly diagnosed type 2 diabetes [81]. Con-
ducted from a societal perspective over a lifetime horizon,
and based on 1999US prices, they estimated an incremental
cost-effectiveness ratio of $7500 per QALY gained when
comparedwith routine prescription ofACE inhibitors for all
patients who were screened for microalbuminuria. Screen-
ing for proteinuria (i.e. identifying patients with overt di-
abetic nephropathy) had the highest cost and the lowest
benefit [82].
Conclusion
In Europe, although some progress has been made against
ESRD caused by glomerulonephritis, urological interstitial
nephritis or type 1 diabetes, the incidence of ESRD caused
by hypertensive renovascular disease or type 2 diabetes
continues to increase [1]. ESRD related to type 2 diabetes
is associated with increased cardiovascular morbidity and
mortality [9,11], and with a relevant financial burden to
third party payers [82,83]. These high ESRD costs, cou-
pled with World Health Organization projections for future
increased prevalence rates of type 2 diabetes [14], clearly
outline the need for improved preventive strategies designed
to target various ESRD ‘precursors’.
Several strategies for intervention are available; however,
the effectiveness of such strategies leaves many patients
with a high residual risk. Early intervention strategies ap-
pear more effective in reducing the risk, and moreover, the
pharmacoeconomic profiles of early intervention clearly
outweigh those of late intervention, despite the fact that
many more patients need to be treated. In that respect, our
findings are in line with those in a previous review [66].
Whether prevention of type 2 diabetes itself should be at-
tempted is a major question and a challenge for the patients
at risk, for clinicians, in terms of choice of drugs to use
and for pharmacoeconomists, in terms of the complexities
involved in the construction of pharmacoeconomic models
for cost analysis and comparison.
Despite the availability of consistent clinical data on the
prevention of renal complications in patients with type 2
diabetes [46,84], these drugs are greatly underutilized ac-
cording to treatment guidelines [85]. Our economic evi-
dence on favourable cost-effectiveness supports further in-
creased efforts to enhance adhering to diabetesmanagement
guidelines.
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